(Press-News.org) Key Takeaways
Immune thrombotic thrombocytopenic purpura, a rare blood clotting disorder, results from an autoimmune attack against an enzyme called ADAMTS13
A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura
Results from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial
A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting throughout the small blood vessels. The group describes the first clinical use of the drug for iTTP in the New England Journal of Medicine.
“The drug is a genetically engineered version of the missing enzyme in iTTP, and we showed that it was able to reverse the disease process in a patient with an extremely severe form of this condition,” said lead author Pavan K. Bendapudi, MD, an investigator in the Division of Hematology and Blood Transfusion Service at Massachusetts General Hospital and an assistant professor of Medicine at Harvard Medical School.
iTTP results from an autoimmune attack against an enzyme called ADAMTS13 that is responsible for cleaving a large protein involved in blood clotting. The current mainstay of therapy for this life-threatening blood disorder is plasma exchange, which removes the harmful autoantibodies and provides extra ADAMTS13. Plasma exchange induces a clinical response in most patients but can restore at best only about half of normal ADAMTS13 activity. By contrast, a recombinant form of human ADAMTS13 (rADAMTS13) offers the possibility of greatly increased ADAMTS13 delivery.
rADAMTS13 was recently approved for patients with congenital thrombotic thrombocytopenic purpura, which occurs in patients born with complete loss of the ADAMTS13 gene. It's questionable whether rADAMTS13 could be effective in iTTP given the presence of inhibitory anti-ADAMTS13 autoantibodies, but Bendapudi and his colleagues received permission from the US Food and Drug Administration to utilize rADAMTS13 donated from the manufacturer under a compassionate use protocol in a dying patient with treatment-resistant iTTP.
“We found that rADAMTS13 rapidly reversed this patient’s disease process despite the current dogma that inhibitory autoantibodies against ADAMTS13 would render the drug useless in this condition,” said Bendapudi. “We were the first physicians to use rADAMTS13 to treat iTTP in the United States, and in this case it helped to save the life of a young mother.”
Bendapudi noted that the infused rADAMTS13 overwhelmed the inhibitory autoantibodies in the patient and reversed the thrombotic effects of iTTP. This impact was observed almost immediately upon administration of rADAMTS13, after daily plasma exchange had failed to induce remission.
“I think rADAMTS13 has the potential to replace the current standard of care in acute iTTP. We will need larger, well-designed trials to evaluate this possibility,” said Bendapudi.
A phase 2b randomized clinical trial of rADAMTS13 in iTTP was recently initiated.
Authorship:
Pavan K. Bendapudi, Brody H. Foy, Sarah B. Mueller, Jun Liu, Louis M. Feingold, Kristen E. Burke, Wendy Cruz, Maria Y. Chen, Emily S. Lau, Rachel L. Goldberg, Ishan Tatake, Shelby C. Wilkinson, Brian J. Carney, James R. Stone, Doyun Park, Alzira Rocheteau Monteiro Avelino, Sajjad Hassan, Chester Andrzejewski, Kristen N. Ruby, Kenneth D. Friedman, Patricia A.R. Brunker, Rebecca K. Leaf, John Higgins, Walter H. Dzik, Jonathan A. Stefely, and Robert S. Makar.
Funding:
Research support was provided by the National Institutes of Health and the Luick Family Fund of the Department of Pathology at Massachusetts General Hospital.
Paper cited:
Bendapudi, P. K., Foy, B. H., Mueller, S. B., Liu, J., Feingold, L. M., Burke, K. E., Cruz, W., Chen, M. Y., Lau, E. S., Goldberg, R. L., Tatake, I., Wilkinson, S. C., Carney, B. J., Stone, J. R., Park, D., Avelino, A. R., Hassan, S., Andrzejewski, C., Ruby, K. N., Friedman, K. D., … Makar, R. S. (2024). Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. The New England journal of medicine, 390(18), 1690–1698. https://doi.org/10.1056/NEJMoa2402567
END
Clinicians report success with first test of drug in a patient with life-threatening blood clotting disorder
Results from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial
2024-05-17
ELSE PRESS RELEASES FROM THIS DATE:
NIH study shows chronic wasting disease unlikely to move from animals to people
2024-05-17
WHAT:
A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people. The findings, from National Institutes of Health scientists and published in Emerging Infectious Diseases, are consistent with decades of similar research in animal models at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Prion diseases are degenerative diseases found in some mammals. These diseases primarily involve deterioration of the brain but also can affect the eyes and other organs. ...
Scientists discover mechanism of sugar signaling in plants
2024-05-17
UPTON, N.Y. — Proteins are molecular machines, with flexible pieces and moving parts. Understanding how these parts move helps scientists unravel the function a protein plays in living things — and potentially how to change its effects. Biochemists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and colleagues at DOE’s Pacific Northwest National Laboratory (PNNL) have just published a new example of how one such molecular machine works.
Their paper in the journal Science Advances describes how the moving parts of ...
Cleveland Clinic research finds VISTA directly blocks T-cells from functioning in immunotherapy
2024-05-17
A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
The study, published in Science Immunology, explains that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote bone and fat development. When VISTA binds to LRIG1, the researchers found, LRIG1 sends signals that suppress T cell replication, survival ...
Pagan-Christian trade networks supplied horses from overseas for the last horse sacrifices in Europe
2024-05-17
Horses crossed the Baltic Sea in ships during the Late Viking Age and were sacrificed for funeral rituals, according to research from Cardiff University.
Published in the journal Science Advances, studies on the remains of horses found at ancient burial sites in Russia and Lithuania show that they were brought overseas from Scandinavia utilising expansive trade networks connecting the Viking world with the Byzantine and Arab Empires.
Up to now, researchers had believed sacrificial horses were always locally-sourced stallions. ...
University of Bristol researchers develop world’s smallest quantum light detector on a silicon chip
2024-05-17
Researchers at the University of Bristol have made an important breakthrough in scaling quantum technology by integrating the world’s tiniest quantum light detector onto a silicon chip.
A critical moment in unlocking the information age was when scientists and engineers were first able to miniaturise transistors onto cheap micro-chips in the 1960s.
Now, for the first time, University of Bristol academics have demonstrated the integration of a quantum light detector – smaller than a human hair – onto a silicon chip, moving us one step closer to the age of quantum technologies using light.
Making high performance electronics ...
Gut bacteria boost immune response to fight tumors
2024-05-17
Roughly one in five cancer patients benefits from immunotherapy – a treatment that harnesses the immune system to fight cancer. Such an approach to beating cancer has seen significant success in lung cancer and melanoma, among others. Optimistic about its potential, researchers are exploring strategies to improve immunotherapy for cancers that don’t respond well to the treatment, with the hope of benefiting more patients.
Now, researchers at Washington University School of Medicine in St. Louis have found, in ...
How heatwaves are affecting Arctic phytoplankton
2024-05-17
The basis of the marine food web in the Arctic, the phytoplankton, responds to heatwaves much differently than to constantly elevated temperatures. This has been found by the first targeted experiments on the topic, which were recently conducted at the Alfred Wegener Institute’s AWIPEV Station. The phytoplankton’s behaviour primarily depends on the cooling phases after or between heatwaves, as shown in a study just released in the journal Science Advances.
Heatwaves, which we’ve increasingly seen around the globe in recent years, are also becoming more and ...
NUS scientist Professor Lim Chwee Teck elected Fellow of the Royal Society
2024-05-17
Professor LIM Chwee Teck, Director of the Institute for Health Innovation & Technology at the National University of Singapore (NUS iHealthtech) and NUSS Professor, has been elected to the prestigious Fellowship of the Royal Society, in recognition of his invaluable contributions to science.
The Royal Society is the world's oldest and most esteemed scientific academy in continuous existence, as well as the United Kingdom’s national academy of sciences. Fellows are elected annually, and candidates are evaluated based on their exceptional achievements in science. This ...
Modern plant enzyme partners with surprisingly ancient protein
2024-05-17
UPTON, N.Y. — Scientists from the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have discovered that a protein responsible for the synthesis of a key plant material evolved much earlier than suspected. This new research explored the origin and evolution of the biochemical machinery that builds lignin, a structural component of plant cell walls with significant impacts on the clean energy industry.
When the first land plants emerged from aquatic environments, they needed to adapt in order to survive.
Chang-Jun Liu, a senior scientist in Brookhaven’s Biology ...
Ion irradiation offers promise for 2D material probing
2024-05-17
Two-dimensional materials such as graphene promise to form the basis of incredibly small and fast technologies, but this requires a detailed understanding of their electronic properties. New research demonstrates that fast electronic processes can be probed by irradiating the materials with ions first.
A collaboration involving researchers at the University of Illinois Urbana-Champaign and the University of Duisburg-Essen has shown that when graphene is irradiated with ions, or electrically charged atoms, the electrons that are ejected ...
LAST 30 PRESS RELEASES:
Youngest in class at higher risk of mental health problems
American Heart Association announces new volunteer leaders for 2025-26
Gut microbiota analysis can help catch gestational diabetes
FAU’s Paulina DeVito awarded prestigious NSF Graduate Research Fellowship
Champions for change – Paid time off initiative just made clinical trials participation easier
Fentanyl detection through packaging
Prof. Eran Meshorer elected to EMBO for pioneering work in epigenetics
New 3D glacier visualizations provide insights into a hotter Earth
Creativity across disciplines
Consequences of low Antarctic sea ice
Hear here: How loudness and acoustic cues help us judge where a speaker is facing
A unique method of rare-earth recycling can strengthen the raw material independence of Europe and America
Epilepsy self-management program shows promise to control seizures, improve mood and quality of life
Fat may play an important role in brain metabolism
New study finds no lasting impact of pandemic pet ownership on human well-being
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
Gut microbes could protect us from toxic ‘forever chemicals’
Novel modelling links sea ice loss to Antarctic ice shelf calving events
Scientists can tell how fast you're aging from a single brain scan
U.S. uterine cancer incidence and mortality rates expected to significantly increase by 2050
Public take the lead in discovery of new exploding star
What are they vaping? Study reveals alarming surge in adolescent vaping of THC, CBD, and synthetic cannabinoids
ECMWF - delivering forecasts over 10 times faster and cutting energy usage by 1000
Brazilian neuroscientist reveals how viral infections transform the brain through microscopic detective work
Turning social fragmentation into action through discovering relatedness
Cheese may really be giving you nightmares, scientists find
Study reveals most common medical emergencies in schools
Breathable yet protective: Next-gen medical textiles with micro/nano networks
Frequency-engineered MXene supercapacitors enable efficient pulse charging in TENG–SC hybrid systems
Developed an AI-based classification system for facial pigmented lesions
[Press-News.org] Clinicians report success with first test of drug in a patient with life-threatening blood clotting disorderResults from this first use of the drug for this condition—by a team led by researchers from Massachusetts General Hospital—warrants testing the drug in a clinical trial